Pancreatic Cancer Research

ResearcherUniversity Hospital UlmActive in the last 2 years

Salah‐Eddin Al‐Batran

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0279-8509; OpenAlex author ID A5072163653. Sources: ClinicalTrials.gov.

Their work

Papers
5 (first author 1, last author 1)
Trials
3
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2014: 1 paper, 1 trial · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 trial · 2020: 1 trial · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 5

  1. Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform… First author DOI 10.1002/ijc.70280↗
  2. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Last author DOI 10.1245/s10434-024-15011-7↗
  3. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
  4. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000441310↗
  5. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Co-author DOI 10.1159/000358890↗

Trials 3

  1. The PLATON Network Study director NCT05489250↗
  2. PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer Study director NCT04119362↗
  3. Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program Study director NCT02691052↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thorsten Oliver Goetze · 2 shared papers, 2024–2026 · strength 0.40
  2. Prof. Dr. Arndt Vogel · 1 shared trial, 2020 · strength 0.36
  3. Prof. Thorsten Goetze · 1 shared trial, 2019 · strength 0.24
  4. Prof. Ralf Hofheinz · 1 shared trial, 2019 · strength 0.24
  5. Ralf‐Dieter Hofheinz · 1 shared paper, 2026 · strength 0.23
  6. Marino Venerito · 1 shared paper, 2024 · strength 0.16
  7. Helmut Oettle · 2 shared papers, 2014–2015 · strength 0.11
  8. Michael Geißler · 1 shared paper, 2014 · strength 0.06
  9. Thomas Theodor Werner Seufferlein · 1 shared paper, 2014 · strength 0.06
  10. Ruben R. Plentz · 1 shared paper, 2015 · strength 0.05
  11. Frank Kullmann · 1 shared paper, 2015 · strength 0.05
  12. Volker Kunzmann · 1 shared paper, 2015 · strength 0.05
  13. Arndt Vogel · 1 shared paper, 2015 · strength 0.05
  14. Christoph Springfeld · 1 shared paper, 2015 · strength 0.05
  15. Jens Thomas Siveke · 1 shared paper, 2015 · strength 0.05
  16. Hanno B. Riess · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.